LOCALIZATION OF APOLIPOPROTEIN(A) AND B-100 IN VARIOUS RENAL DISEASES

被引:68
作者
SATO, H
SUZUKI, S
UENO, M
SHIMADA, H
KARASAWA, R
NISHI, S
ARAKAWA, M
机构
[1] Department of Medicine (II), Niigata University, School of Medicine, Niigata
[2] Division of Internal Medicine, Akita Red Cross Hospital, Akita 010
关键词
D O I
10.1038/ki.1993.63
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Recently it has become clear that abnormalities of lipid metabolism play a large role in the progression of renal diseases. To investigate the relationship between lipids and kidney tissue, we employed an immunofluorescent technique to determine the localization pattern of apolipoprotein(a) [apo(a)], apoB-100, and low-density lipoprotein receptor in the glomeruli, and analyzed the relationship between their presence and the clinical and histological findings of a total 92 patients with glomerular diseases. Immunostaining showed co-localization of apo(a) and apoB-100 in glomeruli. The patients were divided into three groups, as follows: both apo(a) and apoB-100 positive (Group 1; 38 cases), apo(a) positive only (Group 2; 19 cases) and apo(a) negative (Group 3; 35 cases). Group 1 had more severe proteinuria, higher levels of lipoprotein(a) [Lp(a)], and lower total protein levels than Group 3. Group 1 had a higher prevalence of glomerulosclerosis and interstitial changes than Group 3. Group 2 had more severe proteinuria and a higher prevalence of glomerulosclerosis than Group 3. Although apo(a) and apoB-100 are almost absent in normal controls, these apoproteins [and presumably lipoproteins Lp(a)] are present in the glomeruli of patients with glomerular diseases. The data support the view that these apoproteins play a significant role in progressive renal diseases.
引用
收藏
页码:430 / 435
页数:6
相关论文
共 35 条
[1]  
ANDERSON RGW, 1986, METHOD ENZYMOL, P201
[2]  
BADR KF, 1991, SEMIN NEPHROL, V11, P332
[3]   SERUM LIPID AND LIPOPROTEIN ALTERATIONS IN NEPHROSIS [J].
BAXTER, JH ;
GOODMAN, HC ;
HAVEL, RJ .
JOURNAL OF CLINICAL INVESTIGATION, 1960, 39 (03) :455-465
[4]  
BEISIEGEL U, 1981, J BIOL CHEM, V265, P4071
[5]  
DIAMOND JR, 1991, KIDNEY INT, V39, pS29
[6]  
FUNABIKI K, 1990, CLIN NEPHROL, V34, P239
[7]   FURTHER CHARACTERIZATION OF THE CELLULAR PLASMINOGEN BINDING-SITE - EVIDENCE THAT PLASMINOGEN-2 AND LIPOPROTEIN-ALPHA COMPETE FOR THE SAME SITE [J].
GONZALEZGRONOW, M ;
EDELBERG, JM ;
PIZZO, SV .
BIOCHEMISTRY, 1989, 28 (06) :2374-2377
[8]   THE LDL RECEPTOR PATHWAY DELIVERS ARACHIDONIC-ACID FOR EICOSANOID FORMATION IN CELLS STIMULATED BY PLATELET-DERIVED GROWTH-FACTOR [J].
HABENICHT, AJR ;
SALBACH, P ;
GOERIG, M ;
ZEH, W ;
JANSSENTIMMEN, U ;
BLATTNER, C ;
KING, WC ;
GLOMSET, JA .
NATURE, 1990, 345 (6276) :634-636
[9]   LIPOPROTEIN(A) MODULATION OF ENDOTHELIAL-CELL SURFACE FIBRINOLYSIS AND ITS POTENTIAL ROLE IN ATHEROSCLEROSIS [J].
HAJJAR, KA ;
GAVISH, D ;
BRESLOW, JL ;
NACHMAN, RL .
NATURE, 1989, 339 (6222) :303-305
[10]   PLASMIN CATALYZES BINDING OF LIPOPROTEIN (A) TO IMMOBILIZED FIBRINOGEN AND FIBRIN [J].
HARPEL, PC ;
GORDON, BR ;
PARKER, TS .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (10) :3847-3851